Skip to main content
. Author manuscript; available in PMC: 2018 Nov 30.
Published in final edited form as: Pharmacol Ther. 2017 Aug 19;183:50–57. doi: 10.1016/j.pharmthera.2017.08.008

Fig. 3.

Fig. 3.

Increasing the Efficacy of LIF by Targeting LIFR Activity.

Excess activation by LIF triggers the phosphorylation of Ser1044 on LIFR by ERK1/2. Once LIFR is phosphorylated, it is endocytosed by the cell and degraded via the lysosomes. Several drugs may be used to target this process, including PD98059, an ERK inhibitor and Chloroquine, an anti-malarial drug that inhibits lysosomal activity.